Defiance Nasdaq Junior Biotechnology ETF

IBBJ tracks a market-cap-weighted index of small-cap biotech and pharmaceutical companies listed on the NASDAQ.

Invesco BulletShares 2021 USD Emerging Markets Debt ETF

Invesco BulletShares 2021 Corporate Bond ETF

Invesco BulletShares 2021 High Yield Corporate Bond ETF

Invesco BulletShares 2021 Municipal Bond ETF

iShares iBonds Dec 2021 Term Muni Bond ETF

Principal Exchange-Traded Funds - Principal International Multi-Factor Core Index ETF

Plus, a large number of name and index changes occurred during the past two weeks.

ETF Odds & Ends: Closures Accelerate

FT Cboe Vest Buffered Allocation Growth ETF

FT Cboe Vest Buffered Allocation Defensive ETF

Pacer Pacific Asset Floating Rate High Income ETF

AdvisorShares Madrona Global Bond ETF

AS Sage Cr Resr Shs

Impact Shares NAACP Minority Empowerment ETF 

Simplify US Equity PLUS Downside Convexity ETF

Plus, expense ratio changes and other ETF developments occurred during the week.

ETF Odds & Ends: Launches Resurge

Moderna

Invesco Dynamic Biotechnology & Genome ETF

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that offers protection against both the coronavirus and the seasonal flu. The new vaccine booster, which the biotech company calls mRNA-1073, combines Moderna's current coronavirus vaccine [.

Biotech ETFs Benefit From Moderna Dual Booster Shot News

ProShares Ultra Nasdaq Biotechnology

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This follows the Monday news that the FDA fully approved the Pfizer and BioNTech COVID-19 vaccine, making it the first vaccine in the U.S. [.

Could Biotech ETFs Get Another Boost From JNJ News?

Smaller biotechnology stocks aren't setting the world on fire this year, but some analysts believe it's a matter of when, not if, that situation reverses. Should small biotechnology names get their respective grooves back, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one fund to keep an eye out for.

When Will Smaller Biotech Firms Get Their Big Break?

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Pfizer

ALPS Medical Breakthroughs ETF

Trillium Therapeutics

SPDR S&P Biotech ETF

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be awarded such a designation. The move could generate additional confidence for more businesses, schools, and universities to embrace the current vaccine mandates.

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could be the ETF to watch.

Bet on Biotech Small Caps to Bounce Back

Corning

iShares Gold Trust

Oracle

Invesco NASDAQ Next Gen 100 ETF

Silvergate Capital Corp

Unum

Stock markets run on fear and greed in the short term. Here are seven stocks to buy that look like they have significant long-term upside.

7 Stocks to Buy Now if You're Feeling Greedy While Others Are Fearful

Annovis Bio

Arvinas Inc

Anavex Life Sciences

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Principal Healthcare Innovators Index ETF

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

abrdn Healthcare Investors 

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Global X Longevity Thematic ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

Defiance Next Gen Connectivity ETF

Defiance Next Gen H2 ETF

Defiance Quantum ETF

Defiance Next Gen SPAC Derived ETF

Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)

Small cap stocks are retreating. So are biotechnology names.

Why Small Cap Biotech ETFs Are Still Brilliant Bets

The rise in thematic ETFs in 2020 was remarkable, with assets increasing by 78% in Q4 alone, to $104B in AUM. This meteoric growth has been powered by firms like Defiance, a relative newcomer to the ETF space that has already produced a $1B fund in FIVG.

Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast)

After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded funds that target the small and mid cap segments. According to Dealogic data, total deal volume for the drug industry reached $253 billion globally in [.

Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021

Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4% by the afternoon, while the Defiance Nasdaq Junior Biotechnology ETF and the SPDR S&P Biotech ETF both gained 3.5%.

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

There are recipes for success for new exchange-traded funds. In an effort to attract assets and investors' attention, rookie ETFs can undercut established rivals on fees, offer exposure to a compelling theme or get off to strong starts in terms of total returns.

New Biotech ETF Quick To Strut Its Stuff

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it's already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ tracks the Nasdaq Junior Biotechnology Index (NBIJR), which is home to nearly 180 stocks.

Young But Hungry: A New Defiance ETF is Defying Expectations

NEW YORK--(BUSINESS WIRE)---- $IBBJ #Biotech--About Defiance: Founded in 2018, Defiance ETFs is an exchange-traded funds (ETFs) sponsor and registered investment advisor, focused on thematic investing. Defiance's organic growth, driven by our innovative first-mover ETFs and cutting-edge digital footprint, has made Defiance into one of the most dynamic investment brands. Our suite of rules-based ETFs allows retail investors, financial advisors and institutions to express a targeted view on subsectors that are lead

IBBJ ETF, the Junior Biotech ETF Outperforming Nasdaq Biotechnology Index

Roundhill Sports Betting & iGaming ETF

Invesco Global Clean Energy Portfolio

Invesco S&P 500 Equal Weight Materials ETF

After a superb August, September looks gloomy for Wall Street. Still,

"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs

iShares Genomics Immunology and Healthcare ETF

Marinus Pharmaceuticals

Novus Therapeutics

Invesco DWA Healthcare Momentum ETF

Wave Life Sciences

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Healthcare ETFs, Stocks That Gained Double Digits Last Week

Global X Lithium & Battery Tech ETF

The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.

4 Best-Performing Sector ETFs of Last Week

Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.

3 ETFs To Play Gilead's $21B Immunomedics Takeover

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ tracks the Nasdaq Junior Biotechnology Index (NBIJR), which is home to 177 stocks.

Small-Cap Biotechnology ETF Brings Big Opportunity

News for Defiance Nasdaq Junior Biotechnology ETF ETF (IBBJ)